(secondQuint)EC905 Pharmacokinetic Profile Study.

 There will be 3 dose cohorts of 15 subjects each.

 In Period 1, subjects will be randomized to either receive multiple doses of both tamsulosin HCl and solifenacin succinate as single entity tablets, or the combination tablet EC905.

 The alternate treatment will be provided in Period 2.

 The cohorts will be balanced for period effects and first-order carry over effects.

.

 EC905 Pharmacokinetic Profile Study@highlight

A study to compare the pharmacokinetics of tamsulosin HCl and solifenacin succinate after co-administration of single entity tablets and of the combination tablet EC905 under steady state conditions at three dose strengths.

